Navigation Links
Global Standardization for Alzheimer's Biomarkers Moves a Major Step Closer to Reality
Date:8/11/2011

NEW YORK, Aug. 11, 2011 /PRNewswire/ -- Citeline, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials recently reviewed the findings from the 14th International Conference on Alzheimer's Disease (ICAD 2011/AAIC 2011) July 16-21, 2011, noting that while pharma continues to develop beta amyloid targeting drugs, amyloid targets are moving ahead in terms of biomarkers and early warning for risk of Alzheimer's.

According to Dr. Revati Tatake, CNS Analyst at Citeline, noteworthy among the biomarkers/genomics-focused on-going studies were multiple studies under the worldwide initiative, "Alzheimer's Disease Neuroimaging Initiative (ADNI)", spearheaded by the Alzheimer's Association in an effort to globally standardize Alzheimer's biomarkers, and the "Dominantly Inherited Alzheimer's Network (DIAN)" study.  The results from three ADNI studies from different countries suggested that a worldwide ADNI data set can be used for combined analysis of APOE-e4 on amyloid deposition, a step closer to the goal of global standardization of biomarkers. The DIAN study has a slightly different focus and indicated that abnormal levels of CSF amyloid-beta42 and tau protein, brain chemistry and imaging changes can be detected at least 10 years and up to 20 years before the expected onset of Alzheimer's in the subjects with genetic predisposition.

"The progress in Alzheimer's biomarkers/genomics field is especially significant as several clinical studies involving anti-Alzheimer's drugs are investigating CSF/plasma/brain amyloid-beta levels as one of the major efficacy biomarkers and using APOE-e4 genotype for stratifying patients for the treatment," commented Dr. Tatake.  In fact out of the 40 abstracts involving pipeline drugs presented at this meeting, 14 trials contained analysis of biomarker and/or genomic parameters.

A late breaking report concerning long-term safety results of an ongoing Phase II trial of bapineuzumab beyond 78 weeks is worth mentioning.  The long term safety data that bapineuzumab was generally well-tolerated and side-effects tended to be mild and less frequent over time are certainly encouraging, as bapineuzumab is one of the most advanced anti- beta amyloid antibodies that are in clinical development.  Bapineuzumab, jointly developed by Pfizer and J&J, is currently in several ongoing pivotal trials.

Among other approaches targeting the beta amyloid pathway, AFFiRiS/GSK presented safety data for active immunotherapy approach by AFFITOPE AD02.  Bristol-Myers Squibb and Chiesi presented safety and tolerably results of their gamma secretase inhibitors, avagacestat (BMS-708163) and CHF-5074, respectively.   The safety results of gamma secretase inhibitors are particularly important in light of termination of pivotal trials of Lilly's gamma secretase inhibitor, semagacestat, for safety reasons. "It remains to be seen if Lilly's termination of semagacestat has impacted/will impact the course for other gamma secretase inhibitors that are in clinical development," added Dr. Tatake.

About Citeline

Citeline (www.citeline.com) provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 18,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Julie McKenna
Citeline Marketing Manager
617.415.1981


'/>"/>
SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017
2. Generic Drugs in Consumer Health Global Overview 2011
3. Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research
5. Global GMP Guidelines Available in Online GMP Library
6. Robbins & Myers to Present at Jefferies 2011 Global Industrial Conference
7. Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd.
8. Robertson Global Health Solutions Announces Progress Towards Commercial Venture with LifeSense
9. SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion
10. Global Health Ventures to Present Live, Online at RetailInvestorConferences.com on August 4th
11. Global Mercury Treaty May Include Ban on Mercury in Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Calif. , Feb. 24, 2017  In conjunction ... quarter 2016 financial results press release, you are invited ... broadcast live over the internet on Tuesday, March 14, ... Time). A live audio webcast of the ... www.durect.com and clicking "Investor Relations."  If you ...
(Date:2/24/2017)... SILVER SPRING, Md. , Feb. 23, 2017 ... today allowed marketing of the PhenoTest BC Kit, ... first test to identify organisms that cause bloodstream ... organism is likely to respond to (antibiotic sensitivity). ... it takes to provide this important information, which ...
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Healthcare Associates of McKinney announced today that ... at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in ... , As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top ... mannequin art competition. Selected from 15 submissions from around the nation, the top five ... annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the ...
(Date:2/24/2017)... MI (PRWEB) , ... February 24, 2017 , ... ... in Charlevoix, once again hosted their Military Wedding Giveaway, with the winning ... hosted by Castle Farms with services generously donated from local vendors: A Matter ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
Breaking Medicine News(10 mins):